Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Mayer, Jiří ^a   Arthur, Christopher ^b   Delaunay, Jacques ^c   Mazur, Grzegorz ^d   Thomas, Xavier G ^e,i   Wierzbowska, Agnieszka ^f   Ravandi, Farhad ^g   Berrak, Erhan ^h   Jones, Mark ^h   Li, Yuhan ^h   Kantarjian, Hagop M ^g  

^a CENTRAL EUROPEAN INSTITUTE OF TECHNOLOGY   (Czech Republic)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h EISAI INC   (United States)

ⁱ CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Acute Myelocytic Leukemia; Decitabine; Elderly; Treatment

Indexed keywords

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CYTARABINE; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; INTERNATIONALITY; LEUKEMIA, MYELOID, ACUTE; MALE; MULTIVARIATE ANALYSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84893204483     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-69     Document Type: Article

References (14)

1. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474. 10.1182/blood-2009-07-235358, 19880497.
2. Fey MF, Dreyling M. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(suppl 5):v158-v161.
3. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. v.2.2013 2013, Fort Washington, PA: National Comprehensive Cancer Network, Available at: [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site]. Accessed: 1-28-2014, National Comprehensive Cancer Network.
4. Dacogen [Summary of Product Characteristics] 2013, London, United Kingdom: European Medicines Agency, Available at: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002221/human_med_001589.jsp&mid=WC0b01ac058001d124]. Accessed: 1-28-2014.
5. Dacogen [package insert] 2010, Woodcliff Lake, NJ: Eisai Inc.
6. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109:52-57. 10.1182/blood-2006-05-021162, 16882708.
7. Cashen AF, Schiller GJ, O'Donnell MR, Dipersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010, 28:556-561. 10.1200/JCO.2009.23.9178, 20026803.
8. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau J-P, Chou W-C, Buckstein R, Cermak J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012, 30:2670-2677. 10.1200/JCO.2011.38.9429, 22689805.
9. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest oncology group/Eastern cooperative oncology group study. Blood 2000, 96:4075-4083.
10. Bennett JM, Young ML, Andersen JW, Cassileth PA, Tallman MS, Paietta E, Wiernik PH, Rowe JM. Long-term survival in acute myeloid leukemia: the Eastern cooperative oncology group experience. Cancer 1997, 80:2205-2209. 10.1002/(SICI)1097-0142(19971201)80:11+<2205::AID-CNCR7>3.0.CO;2-G, 9395035.
11. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1302-1311. 10.1182/blood.V98.5.1302, 11520775.
12. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485. 10.1182/blood-2005-09-3724, 1895766, 16455952.
13. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106:1090-1098. 10.1002/cncr.21723, 16435386.
14. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569. 10.1200/JCO.2009.23.8329, 20026804.